https://www.fool.com/investing/general/2011/05/03/medtronic-is-target-of-new-senate-finance-committe.aspx
https://www.fool.com/investing/general/2011/07/15/st-jude-medicals-novel-heart-disease-diagnostic-to.aspx
https://www.fool.com/investing/general/2011/12/06/senators-question-pfizer-lipitor-deals-ranbaxy-get.aspx
https://www.fool.com/investing/general/2011/07/27/is-private-equity-interested-in-buying-ppd.aspx
https://www.fool.com/investing/general/2011/06/27/cardinal-health-products-wont-be-in-cleveland-medi.aspx
https://www.fool.com/investing/general/2011/04/30/ipad-makes-medtronic-more-than-just-cool.aspx
https://www.fool.com/investing/general/2011/11/08/cardinal-health-looks-to-build-china-business-but-.aspx
https://www.fool.com/investing/general/2011/11/14/safeguard-scientifics-health-it-could-grow-to-one-.aspx
https://www.fool.com/investing/general/2011/07/21/new-hypertension-treatment-from-st-jude-medical.aspx
https://www.fool.com/investing/general/2011/07/16/medtronic-invests-in-california-eye-lens-implant-c.aspx
https://www.fool.com/investing/general/2011/11/02/invacare-sees-potential-in-long-term-care-equipmen.aspx
https://www.fool.com/investing/general/2011/04/05/tranzyme-pharmas-public-offering-raises-48m-but-ip.aspx
https://www.fool.com/investing/general/2011/06/01/philip-morris-buys-smokeless-nicotine-technology-f.aspx
https://www.fool.com/investing/general/2011/08/24/growth-is-the-deity-medtronic-ceo-omar-ishrak-will.aspx
https://www.fool.com/investing/general/2011/07/12/fda-allows-expansion-of-st-jude-study-to-treat-sev.aspx
https://www.fool.com/investing/general/2011/05/10/salix-sued-by-partner-for-breach-over-hiv-associat.aspx
https://www.fool.com/investing/general/2011/10/29/ibms-watson-offers-a-glimpse-into-health-its-futur.aspx
https://www.fool.com/investing/general/2011/08/04/medtronic-infuse-device-will-be-reviewed-by-yale-r.aspx
https://www.fool.com/investing/general/2011/04/29/medtronic-stands-to-gain-from-likely-cms-reversal-.aspx
https://www.fool.com/investing/general/2011/04/23/st-jude-medtronic-execs-offer-different-views-on-j.aspx
https://www.fool.com/investing/general/2011/08/04/skin-in-the-game-how-acne-skin-care-fits-gsks-drug.aspx
https://www.fool.com/investing/general/2011/04/20/growing-cro-demand-boosts-outlook-for-kendle.aspx
https://www.fool.com/investing/general/2011/04/28/nc-health-it-firm-bloodhound-acquired-by-verisk-an.aspx
https://www.fool.com/investing/general/2011/04/15/gsk-to-shed-weight-loss-drug-alli-and-18-others.aspx
https://www.fool.com/investing/general/2011/05/19/medtronic-ford-developing-in-car-diabetes-manageme.aspx
https://www.fool.com/investing/general/2011/04/12/endo-acquires-pelvic-care-firm-american-medical-sy.aspx
https://www.fool.com/investing/general/2011/07/06/infuse-furor-may-force-medtronic-spine-business-sa.aspx
https://www.fool.com/investing/general/2011/11/01/ibms-watson-offers-a-glimpse-into-health-its-futur.aspx
https://www.fool.com/investing/general/2011/12/24/johnson-johnson-recalls-motrin-from-retailers.aspx
https://www.fool.com/investing/general/2011/09/09/gsk-halts-part-of-breast-cancer-trial-drug-cant-to.aspx
https://www.fool.com/investing/general/2011/04/27/medtronic-and-eli-lilly-join-hands-to-combat-parki.aspx
https://www.fool.com/investing/general/2011/04/27/inspires-pink-eye-drug-azasite-draws-generic-chall.aspx
https://www.fool.com/investing/general/2011/09/14/heres-how-new-roche-cancer-drug-zelboraf-benefits-.aspx
https://www.fool.com/investing/general/2011/08/06/medtronic-jobs-firm-will-double-chinese-workforce-.aspx
https://www.fool.com/investing/general/2011/06/21/gsk-hiv-drug-pipeline-sees-boost-as-partner-concer.aspx
https://www.fool.com/investing/general/2011/06/24/data-on-st-jude-migraine-treatment-impressive.aspx
https://www.fool.com/investing/general/2011/06/14/gsk-epilepsy-drug-approved-by-fda.aspx
https://www.fool.com/investing/general/2011/06/03/gsk-sees-positive-results-on-asthma-copd-drug-expe.aspx
https://www.fool.com/investing/general/2011/04/14/biogen-idec-inks-biotech-blood-products-research-d.aspx
https://www.fool.com/investing/general/2011/04/08/medtronic-to-combine-cardiac-and-vascular-sales-fo.aspx
https://www.fool.com/investing/general/2011/11/03/gsk-settles-with-uncle-sam-for-3b.aspx
https://www.fool.com/investing/general/2011/09/15/gsks-new-drug-marketing-model-pharma-reps-as-educa.aspx
https://www.fool.com/investing/general/2011/11/26/pozen-inks-75-million-royalty-deal-for-treximet.aspx
https://www.fool.com/investing/general/2011/05/10/medtronics-mr-conditional-pacemaker-likely-too-exp.aspx
https://www.fool.com/investing/international/2011/04/16/pozen-wins-injunction-blocking-generic-migraine-dr.aspx
https://www.fool.com/investing/general/2011/12/13/nc-novartis-site-is-first-cell-based-flu-vaccine-f.aspx
https://www.fool.com/investing/general/2011/10/10/trgt-tries-again-with-alzheimers-disease-drug-cand.aspx
https://www.fool.com/investing/general/2011/06/08/lorillard-hires-fda-official-to-tackle-tobacco-reg.aspx
https://www.fool.com/investing/general/2011/08/10/athersys-more-threatened-than-most-by-falling-shar.aspx
https://www.fool.com/investing/general/2011/06/27/st-jude-medicals-migraine-treatment-good-for-europ.aspx
https://www.fool.com/investing/general/2011/04/05/gsk-in-emerging-markets-why-sales-staff-there-are-.aspx
https://www.fool.com/investing/general/2011/07/13/fda-oks-study-design-on-medtronic-product-that-fir.aspx
https://www.fool.com/investing/general/2011/08/13/investors-blocking-pfizers-bid-say-icagens-value-c.aspx
https://www.fool.com/investing/general/2011/10/06/duke-university-and-verizon-partner-on-new-health-.aspx
https://www.fool.com/investing/general/2011/06/08/oxygen-biotherapeutics-expands-tbi-trials-to-india.aspx
https://www.fool.com/investing/general/2011/09/02/pfizer-extends-icagen-offer-remains-just-shy-of-sh.aspx
https://www.fool.com/investing/general/2011/05/02/teva-pays-68b-to-buy-cephalon-including-minnesotas.aspx
https://www.fool.com/investing/general/2011/04/29/invacare-lifts-prices-to-offset-rising-commodity-f.aspx
https://www.fool.com/investing/general/2011/12/17/kensey-nash-opts-for-mediation-in-royalties-disput.aspx
https://www.fool.com/investing/general/2011/04/07/generic-wave-to-drive-cardinal-healths-profitabili.aspx
https://www.fool.com/investing/general/2011/08/24/cardinal-health-sees-opportunity-but-faces-challen.aspx
https://www.fool.com/investing/general/2011/05/12/analysts-medtronic-ceo-omar-ishrak-good-choice.aspx
https://www.fool.com/investing/general/2011/09/17/pozens-digital-marketing-plan-a-prescription-for-t.aspx
https://www.fool.com/investing/general/2011/06/07/st-jude-medical-introduces-two-cardiac-devices-in-.aspx
https://www.fool.com/investing/general/2011/04/25/st-jude-new-aortic-replacement-valve-approved.aspx
https://www.fool.com/investing/general/2011/04/22/biogen-idecs-ms-drug-appears-to-have-an-edge.aspx
https://www.fool.com/investing/general/2011/05/28/philip-morris-buys-smokeless-nicotine-technology-f.aspx
https://www.fool.com/investing/general/2011/05/18/quick-to-dough-no-not-pillsbury-flour-but-medtroni.aspx
https://www.fool.com/investing/general/2011/09/09/cardinal-health-looks-to-pet-drugs-to-drive-margin.aspx
https://www.fool.com/investing/general/2011/05/18/targacepts-75m-stock-offering-targets-cognitive-di.aspx
https://www.fool.com/investing/general/2011/09/12/gsk-sues-to-block-generic-bph-drugs-from-mylan-imp.aspx
